1. Effects of vildagliptin, a DPP-4 inhibitor, in elderly diabetic patients with mild cognitive impairment.
- Author
-
Borzì AM, Condorelli G, Biondi A, Basile F, Vicari ESD, Buscemi C, Luca S, and Vacante M
- Subjects
- Aged, Aged, 80 and over, Diabetes Mellitus, Type 2 psychology, Female, Glycated Hemoglobin analysis, Humans, Male, Mental Status and Dementia Tests, Metformin therapeutic use, Retrospective Studies, Cognitive Dysfunction drug therapy, Diabetes Mellitus, Type 2 drug therapy, Dipeptidyl-Peptidase IV Inhibitors therapeutic use, Hypoglycemic Agents therapeutic use, Vildagliptin therapeutic use
- Abstract
Introduction: There is an unclear association between type 2 diabetes and mild cognitive impairment in the elderly. Both diseases are more prevalent in the older adults compared to the younger counterpart. Some anti-diabetic drugs seem to influence positively the evolution of mild cognitive impairment. This retrospective study investigated the effect of vildagliptin, an inhibitor of the enzyme dipeptidyl peptidase-4 (DPP-4), on the cognitive functioning of elderly diabetic patients with mild cognitive impairment (MCI) documented at mini mental state examination (MMSE)., Methods: We included 60 diabetic elderly people which were divided in 2 groups: Group A, 30 patients with HbA
1 c (glycated hemoglobin) ≤7.5% and treated with metformin, and Group B, 30 patients with HbA1 c >7.5%, and treated with metformin plus vildagliptin. We collected data on MMSE, fasting plasma glucose (FPG) and HbA1 c at baseline and after 180 ± 10 days from the beginning of treatment., Results: The two groups exhibited significantly different values in FPG (P < 0.05) and HbA1 c (P < 0.01) at baseline, and in MMSE score (P < 0.001) after treatment. The intragroup comparison showed a significant (P < 0.05) reduction in MMSE score in group A, and in HbA1c (P = 0.01) in group B., Conclusion: Vildagliptin in addition to metformin resulted in the maintenance of MMSE score, showing a protecting role on cognitive functioning compared to the metformin only group., (Copyright © 2019 Elsevier B.V. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF